Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature
10.3779/j.issn.1009-3419.2014.04.09
- VernacularTitle:阿法替尼一线治疗5例晚期肺腺癌患者的不良反应分析及相关文献回顾
- Author:
TAO HONG
1
;
GUO LILI
;
TANG JUNFANG
;
ZHU YUNZHONG
;
XU LIYAN
;
MENG QIYI
;
WU WEI
;
LI MINGZHI
;
WU WEIHUA
;
TONG LI
;
WU HONGBO
;
SHI LIANG
;
LIU ZHE
Author Information
1. 首都医科大学附属北京胸科医院肿瘤内科
- Keywords:
Afatinib;
Epidermal growth factor receptor;
Tyrosine kinase inhibitor;
Lung neoplasms;
Adverse event
- From:
Chinese Journal of Lung Cancer
2014;(4):342-346
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Afatinib is an irreversible ErbB-family blocker with a clinical activity in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. hTe aim of this study is to assess the safety of afatinib in patients with advanced lung adenocarcinoma. Methods Patients with lung adenocarcinoma (stage IIIb or IV) with EGFR mutations were ifrst-line treated with an oral administration of afatinib (40 mg/d) until disease progression. Adverse events, effects, and survival condition were observed. Results hTe most common adverse events were diarrhea (n=5, 100%), skin rash (n=4, 80%), and mucositis/stomatitis (n=4, 80%). Moderate toxicities not exceeding grade 3 were observed. Relatively, the most serious adverse reaction was mucositis/stomatitis. Mild diarrhea occurred in all patients. hTree patients experienced temporary drug withdrawal and dose reduction because of adverse reaction. Among the four patients who were evaluated, partial response was observed in two patients (50%), one with stable disease (25%) and one with progressive disease (25%). Median progression-free survival was 9.7 months, whereas median overall survival was 18.4 months. Conclusion Afa-tinib was approved as ifrst-line treatment for patients with advanced lung adenocarcinoma. hTe most common adverse events were diarrhea and skin rash. However, mucositis/stomatitis related to afatinib should also be considered. Considering the small number of cases, the conclusion requires more trials for conifrmation.
